e-learning
resources
Milan 2017
Monday, 11.09.2017
PAH and CTEPH
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
L. Nicod (Lausanne, Switzerland)
Source:
International Congress 2017 – PAH and CTEPH
Session:
PAH and CTEPH
Session type:
Thematic Poster
Number:
2414
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Nicod (Lausanne, Switzerland). Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). 2414
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD)
Source: Annual Congress 2004 - Treatment of pulmonary hypertension
Year: 2004
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004
Expression of the serotonin 1b receptor in experimental pulmonary hypertension
Source: Eur Respir J 2003; 22: 408-412
Year: 2003
Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Survival with first-line bosentan in patients with primary pulmonary hypertension
Source: Eur Respir J 2005; 25: 244-249
Year: 2005
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Involvement of the pulmonary micro-vasculature in chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept